AstraZeneca's Farxiga steps on FDA fast track in kidney disease, setting up J&J battle

27th August 2019 Uncategorised 0

AstraZeneca is on its way to scoring a key new nod for SGLT2 diabetes drug Farxiga, and the FDA just sped things up. Farxiga scored an FDA ‘fast track’ designation for kidney disease patients after an outcomes study showed delayed kidney failure and prevented cardiovascular or kidney-related death.

More: AstraZeneca's Farxiga steps on FDA fast track in kidney disease, setting up J&J battle
Source: fierce